SHIRE PLC (NASDAQ:SHPG) Files An 8-K Other Events
Item 8.01. Other Events
Shire plc has issued the press release attached hereto as Exhibit 99.1, which is incorporated by reference herein.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits. The following exhibit is filed herewith:
99.1Press Release dated January 7, 2019
EXHIBIT INDEX
|
ExhibitNo. |
Description |
| 99.1 | Press Release dated January 7, 2019 |
Shire plc Exhibit
EX-99.1 2 dp100639_ex9901.htm EXHIBIT 99.1 Exhibit 99.1 Press Release www.shire.com Holding(s) in Company January 7,…
To view the full exhibit click here
About SHIRE PLC (NASDAQ:SHPG)
Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. The Company’s products include VYVANSE/VENVANSE/ELVANSE/TYVENSE/ELVANSEVUXEN/ADUVANZ (lisdexamfetamine dimesylate), ADDERALL XR (mixed salts of a single-entity amphetamine), INTUNIV (extended release guanfacine), LIALDA (mesalamine)/MEZAVANT(mesalazine), PENTASA (mesalamine), REPLAGAL (agalsidase alfa), ELAPRASE (idursulfase), VPRIV (velaglucerase alfa), FIRAZYR (icatibant), FOSRENOL (lanthanum carbonate), KALBITOR, CINRYZE C1 esterase inhibitor (human), GATTEX/REVESTIVE, BUMINATE 25% Albumin (Human), BUMINATE 5% Albumin (Human), GLASSIA Alpha1-Proteinase Inhibitor (Human) and ONCASPAR pegaspargase.
